Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +14.83% | +12.89% | +11.87% | +3.63% | +0.40% |
| Weighted Average Shares Diluted Growth | +14.83% | +12.89% | +11.87% | +3.63% | +0.40% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -7.68% | -5.58% | -22.30% | -29.87% | -31.62% |
| Book Value per Share Growth | -23.66% | -20.24% | -47.63% | -58.15% | -64.07% |
| Debt Growth | -22.61% | -25.56% | -27.70% | -30.23% | -33.20% |
| R&D Expense Growth | -16.20% | -41.82% | +16.76% | -45.87% | -57.77% |
| SG&A Expenses Growth | +3.59% | +16.83% | +201.76% | -26.97% | -45.74% |